Galderma Group Forecasts Revised as BofA Notes US FDA Response to Relfydess Application
() -- BofA Global Research adjusted its forecasts for Galderma Group (GALD.SW) as it took note of the second complete response letter from the US Food and Drug Administration for the group's Relfydess neuromodulator. "Management had been cautious since2H25 on the likelihood of an acceptance, considering recent neuromod